Xinhengrui Medical Closes Hundreds of Millions of yuan Series A Financing

Shanghai Xinhengrui Medical Technology Co., Ltd. has recently completed a nearly RMB 100 million (US$ 14 million) Series A financing led by IDG Capital and co-invested by Hygeia Capital and Everest VC, to support the registration, clinical trials, and commercialisation of its first product, OmniHeart percutaneous ventricular assist device.

Founded in May 2021 in Shanghai, Xinhengrui Medical focuses on the research, development and industrialisation of innovative medical devices for heart failure, providing comprehensive, safe and effective intelligent mechanically-assisted therapeutic solutions for heart failure patients. The company’s core staff all have more than 10 years of experience in the medical or related industries, and the R&D team spans fluid, mechanical, electronic, software, materials and other professional fields.

Relying on its core technology platform, Xinhengrui Medical has established a multi-pipeline product layout in the field of mechanical circulation for heart failure diseases. At different stages of heart failure, Xinhengrui Medical can provide the most personalised ventricular assist devices for effective treatment. Xinhengrui Medical has innovatively developed percutaneous ventricular assist device, implantable ventricular assist device and implantable biventricular assist device, which are more suitable for Chinese patients to use mechanical circulatory assist devices.